AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00060255
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv
Trial: NCT00060255
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv
Trial: NCT03134638
Drug: SY-1365 (Cohort 5)
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
Trial: NCT03134638
Drug: SY-1365 (Part 2 Single Agent)
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
Trial: NCT01131585
Drug: Sham injections
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Trial: NCT01131585
Drug: Ranibizumab 0.5 mg
RxNorm normalized name: ranibizumab 0.5 MG in 0.05 ML Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Trial: NCT01261377
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
Trial: NCT00776425
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
Trial: NCT00202995
Drug: Glatiramer Acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg s.c. daily
Trial: NCT00202995
Drug: Betaseron
RxNorm normalized name: Betaseron
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg every other day
Trial: NCT00202995
Drug: Rebif
RxNorm normalized name: Rebif
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 44 ug 3 times a week
Trial: NCT02787798
Drug: valsartan/sacubitril 100 mg
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with 100 mg tablets during 2 to 4 weeks
Trial: NCT02787798
Drug: valsartan/sacubitril 200 mg
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with 200 mg tablets during 2 to 4 weeks
Trial: NCT00360854
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03967665
Drug: N-acetyl-L-cysteine
RxNorm normalized name: N-acetyl-L-cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
Trial: NCT04556825
Drug: PRP
RxNorm normalized name: PRP
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the arthroscopic operation was completed, a local PRP with 4ml was injected
Trial: NCT04253678
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
Trial: NCT00472641
Drug: Ziprasidone/Geodon
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziprasidone/Geodon
Trial: NCT00481104
Drug: Tesofensine
RxNorm normalized name: Tesofensine
DrugBank: Tesofensine (DB06156)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004015
Drug: sodium borocaptate
RxNorm normalized name: Borocaptate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00476541
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two courses of Gemtuzumab vs. no further therapy
Trial: NCT00060255
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv
Trial: NCT00060255
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00060255
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: iv
Trial: NCT04437212
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received toripalimab 240mg every 3 weeks 1-7 days after neoadjuvant chemoradiotherapy for 2 cycles before operation and 28-42 days after operation for 4 cycles.
Trial: NCT01636466
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
Trial: NCT04610658
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.
Trial: NCT00728182
Drug: NA-1
RxNorm normalized name: Na-1
DrugBank: Nerinetide (DB12595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
Trial: NCT04610658
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.
Trial: NCT04610658
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m\^2 and increasing to 3.2 mg/m\^2 or the Maximum Tolerated Dose (MTD)
Trial: NCT05264584
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
Trial: NCT05264584
Drug: Febuxostat 80 MG
RxNorm normalized name: febuxostat 80 MG
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
Trial: NCT01933425
Drug: rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01933425
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01784536
Drug: Single-Dose IV Oritavancin Diphosphate
RxNorm normalized name: Oritavancin Diphosphate
DrugBank: Oritavancin (DB04911)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
Trial: NCT01263028
Drug: Ergocalciferol supplementation
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
Trial: NCT03124433
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive oral apalutamide 240mg daily for 12 weeks
Trial: NCT00227305
Drug: quetiapine fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dosing, flexible dosing
Trial: NCT02366130
Drug: Ra-223 dichloride
RxNorm normalized name: RADIUM RA-223 DICHLORIDE
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
Trial: NCT02366130
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
Trial: NCT03495323
Drug: Prexasertib
RxNorm normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
Trial: NCT03472677
Drug: CNTX-4975-05 (trans-capsaicin)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
Trial: NCT03472677
Drug: CNTX-4975-05 (trans-capsaicin)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
Trial: NCT03472677
Drug: CNTX-4975-05 (trans-capsaicin)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
Trial: NCT03472677
Drug: Capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four intradermal injections of capsaicin, two on each forearm.
Trial: NCT00270166
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01666314
Drug: Orteronel
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orteronel tablets
Trial: NCT01666314
Drug: Orteronel Placebo
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orteronel placebo-matching tablets
Trial: NCT01666314
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 5 mg
Trial: NCT01386177
Drug: 3,4-Methylenedioxymethamphetamine
RxNorm normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg per os, single dose
Trial: NCT01386177
Drug: Doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os.
Trial: NCT02269605
Drug: Bryostatin 1 (10ug/m2)
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Bryostatin 1 (10ug/m2) at single dose
Trial: NCT02269605
Drug: Bryostatin 1 (20ug/m2)
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: Bryostatin 1 (20ug/m2) at single dose
Trial: NCT03492112
Drug: Sofosbuvir/velpatasvir
RxNorm normalized name: SOFOSBUVIR/VELPATASVIR
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
Trial: NCT03492112
Drug: Glecaprevir/pibrentasvir
RxNorm normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
Trial: NCT01559285
Drug: 0.75% ropivacaine concentration
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Trial: NCT01559285
Drug: 0.375% ropivacaine concentration
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Trial: NCT01559285
Drug: 0.2% ropivacaine concentration
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Trial: NCT00114478
Drug: albuterol (salbutamol)
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01972984
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
Trial: NCT03116269
Drug: Cilostazol 100mg
RxNorm normalized name: CILOSTAZOL 100MG TAB
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03116269
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00313898
Drug: sildenafil (viagra)
RxNorm normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03274661
Drug: Pembrolizumab 200 mg Q3W
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
Trial: NCT03921541
Drug: Pegzilarginase
RxNorm normalized name: Pegzilarginase
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Trial: NCT04618965
Drug: Intrathecal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
Trial: NCT04618965
Drug: Intravenous dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
Trial: NCT04212065
Drug: buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
Trial: NCT02046187
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
Trial: NCT01232907
Drug: L-Carnitine
RxNorm normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
Trial: NCT03526432
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
Trial: NCT03526432
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
Trial: NCT02264041
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05862441
Drug: SA
RxNorm normalized name: SA
DrugBank: Sulfanilamide (DB00259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
Trial: NCT04834115
Drug: Ivermectin Tablets
RxNorm normalized name: Ivermectin Tablets
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin at a one time dose
Trial: NCT01805570
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
Trial: NCT01805570
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
Trial: NCT00132912
Drug: SCH 530348
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03868566
Drug: SNP-612 dose1
RxNorm normalized name: SNP-ACTH (1-39)
DrugBank: SNP-ACTH (1-39) (DB18544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take dose1 once a day orally for 12 weeks
Trial: NCT03868566
Drug: SNP-612 dose2
RxNorm normalized name: SNP-ACTH (1-39)
DrugBank: SNP-ACTH (1-39) (DB18544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take dose2 once a day orally for 12 weeks
Trial: NCT01371565
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mifepristone at doses from 300mg/day up to 1200mg/day
Trial: NCT02170012
Drug: PF-06743649
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tablet once daily dosing for 14 days
Trial: NCT02170012
Drug: PF-06743649
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be decided dose, tablet once daily dosing for 14 days
Trial: NCT02852434
Drug: Lidocaine Gel (2%)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02852434
Drug: Lidocaine Paracervical Block (1%)
RxNorm normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04116047
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04116047
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05406999
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg (250 mg×4 tablets) once daily, orally